Atlas Trials

Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers

Clinical trial NCT06083662 · COMPLETED

Trial details

NCT number
NCT06083662
Sponsor
Korea University Guro Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic CancerHER2 Gene Mutation
Start date
2021-06-15
Primary completion
2023-11-30
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.